ASTH or USPH: Which Is the Better Value Stock Right Now?

Astrana Health, Inc. (ASTH) is identified as the superior value stock over U.S. Physical Therapy (USPH) within the Medical - Outpatient and Home Healthcare sector. ASTH carries a Zacks Rank of #1 (Strong Buy) and a Value grade of 'A', underpinned by significantly more favorable valuation metrics including a forward P/E of 20.02 versus USPH's 33.65, a PEG ratio of 0.67 versus 4.40, and a P/B ratio of 2.11 versus 2.65. These factors, combined with an improving earnings outlook, position ASTH as the preferred value investment.

Analysis

A comparative analysis within the Medical - Outpatient and Home Healthcare sector identifies Astrana Health (ASTH) as a more compelling value investment than U.S. Physical Therapy (USPH). This assessment is based on the Zacks Rank system, which highlights ASTH with a #1 (Strong Buy) rating driven by positive earnings estimate revisions, superior to USPH's #2 (Buy) rating. The valuation disparity is stark: ASTH trades at a forward P/E of 20.02, while USPH is significantly more expensive at 33.65. The most critical differentiator is the PEG ratio, where ASTH's 0.67 indicates its price may be low relative to its earnings growth potential, in sharp contrast to USPH's 4.40. This is further supported by ASTH's more favorable Price-to-Book ratio of 2.11 versus 2.65 for USPH. Collectively, these metrics underpin ASTH's 'A' grade for Value, compared to a 'C' for USPH, suggesting a stronger combination of positive earnings momentum and attractive valuation for Astrana Health.

Key Decisions for Investors

• Value-focused investors should consider Astrana Health (ASTH) a primary candidate for investment within the outpatient healthcare space, given its superior valuation metrics and strong earnings outlook indicated by its #1 Zacks Rank.
• Investors currently holding U.S. Physical Therapy (USPH) may wish to re-evaluate their position, as its high forward P/E and PEG ratios suggest the stock is priced at a significant premium to its peer, potentially limiting its near-term upside.
• For any new or existing position in ASTH, it is crucial to monitor future earnings releases to validate that the positive estimate revisions materialize into sustained growth, which is the core driver of its low PEG ratio.